Wall Street brokerages predict that Heron Therapeutics, Inc. (NASDAQ:HRTX) will post earnings per share (EPS) of ($1.01) for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Heron Therapeutics’ earnings, with estimates ranging from ($1.04) to ($0.99). Heron Therapeutics reported earnings of ($1.17) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 13.7%. The firm is scheduled to announce its next earnings report on Monday, August 14th.

On average, analysts expect that Heron Therapeutics will report full year earnings of ($3.74) per share for the current year, with EPS estimates ranging from ($4.15) to ($3.18). For the next financial year, analysts forecast that the company will report earnings of ($1.91) per share, with EPS estimates ranging from ($3.91) to ($0.29). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that that provide coverage for Heron Therapeutics.

Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings results on Wednesday, May 10th. The biotechnology company reported ($1.00) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.94) by $0.06. The company had revenue of $3.63 million during the quarter, compared to analyst estimates of $1.96 million.

A number of research analysts have recently issued reports on HRTX shares. Zacks Investment Research raised Heron Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 7th. Aegis reaffirmed a “buy” rating on shares of Heron Therapeutics in a research note on Tuesday, March 21st. Noble Financial reaffirmed a “buy” rating on shares of Heron Therapeutics in a research note on Friday, May 12th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $31.00 price objective (up from $30.00) on shares of Heron Therapeutics in a research note on Thursday, May 11th. Finally, Cowen and Company reaffirmed a “buy” rating and set a $40.00 price objective on shares of Heron Therapeutics in a research note on Friday, May 26th. One investment analyst has rated the stock with a sell rating and ten have assigned a buy rating to the company. Heron Therapeutics has an average rating of “Buy” and a consensus target price of $34.50.

In other news, VP Kimberly Manhard sold 21,542 shares of the stock in a transaction dated Monday, April 24th. The shares were sold at an average price of $15.33, for a total transaction of $330,238.86. Following the completion of the sale, the vice president now directly owns 5,250 shares in the company, valued at $80,482.50. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 20.31% of the company’s stock.

Several hedge funds have recently bought and sold shares of HRTX. Legal & General Group Plc raised its stake in Heron Therapeutics by 13.9% in the first quarter. Legal & General Group Plc now owns 8,971 shares of the biotechnology company’s stock worth $136,000 after buying an additional 1,098 shares in the last quarter. Venturi Wealth Management LLC purchased a new stake in Heron Therapeutics during the first quarter worth $161,000. Pacad Investment Ltd. purchased a new stake in Heron Therapeutics during the fourth quarter worth $155,000. Old West Investment Management LLC purchased a new stake in Heron Therapeutics during the first quarter worth $206,000. Finally, Highbridge Capital Management LLC raised its stake in Heron Therapeutics by 1.6% in the fourth quarter. Highbridge Capital Management LLC now owns 15,697 shares of the biotechnology company’s stock worth $206,000 after buying an additional 252 shares in the last quarter.

COPYRIGHT VIOLATION NOTICE: “Heron Therapeutics, Inc. (HRTX) Expected to Post Earnings of -$1.01 Per Share” was originally posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/06/22/heron-therapeutics-inc-hrtx-expected-to-post-earnings-of-1-01-per-share.html.

Heron Therapeutics (NASDAQ:HRTX) opened at 15.00 on Thursday. Heron Therapeutics has a 1-year low of $12.21 and a 1-year high of $24.00. The firm’s 50-day moving average price is $14.32 and its 200-day moving average price is $14.12.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Get a free copy of the Zacks research report on Heron Therapeutics (HRTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.